About: Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group
Creator	Nakayama, H Saito, A Takahashi, H Kinoshita, Akitoshi Kiyokawa, Nobutaka Kudo, Kazuko Moritake, Hiroshi Nakayama, Hideki Taga, Takashi Takahashi, Hiroyuki Tawa, Akio Tomizawa, Daisuke Watanabe, T Watanabe, Tomoyuki Akiko, • Akira, Iwamoto Horibe, Á Iwamoto, S Junichi, Mizutani Keiichi, • Keizo, Hara Kiminori Terui, Shimada Kinoshita, A Kiyokawa, N Kudo, K Mizutani, Á Moritake, H Saito, Moriya Shimada, A Shotaro, • Shuki, Isoyama Souichi, Nakahata Taga, T Tatsutoshi, Horibe Tawa, A Terui, K Tomizawa, D
Source	PMC
abstract	Infants (<1 year old) with acute myeloid leukemia (AML) are particularly vulnerable to intensive cytotoxic therapy. Indeed, the mortality rate was high among infants enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study, which prompted us to temporarily suspend patient enrollment and amend the protocol. Forty-five infants with AML were enrolled. For patients aged <2 years, drug doses were adjusted for body weight. Following the protocol amendments, doses for infants were reduced by a further 33 % in the initial induction course. Six infants died during the induction phase (including five early deaths), mainly due to pulmonary complications. The 3-year probability of overall survival (pOS) in all 45 infants [55.9 %, 95 % confidence interval (CI) 37.9–70.6 %] was significantly lower than that of patients aged 1 to <2 years (77.0 %, 95 % CI 62.7–86.3 %) and those aged ≥2 years (74.7 %, 95 % CI 69.2–79.4 %) (P = 0.037), mainly due to the higher non-relapse mortality rate in infants. No early deaths occurred after the protocol amendments, and the 3-year pOS of the 17 infants enrolled thereafter was 76.4 % (95 % CI 48.8–90.4 %). In conclusion, appropriate dose reduction is essential to avoid early deaths when treating infants with AML.
has issue date	2013-09-26(xsd:dateTime)
bibo:doi	10.1007/s12185-013-1429-2
bibo:pmid	24068655
has license	no-cc
sha1sum (hex)	aaa8ff919bdfc01000ce52adc936d939b95b8482
schema:url	https://doi.org/10.1007/s12185-013-1429-2
resource representing a document's title	Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group
has PubMed Central identifier	PMC7101778
has PubMed identifier	24068655
schema:publication	Int J Hematol
resource representing a document's body	covid:aaa8ff919bdfc01000ce52adc936d939b95b8482#body_text
is schema:about of	named entity 'confidence interval' named entity 'aged' named entity 'AML' named entity 'INFANTS' named entity 'INDUCTION' named entity 'HIGHER' named entity 'body weight' named entity 'AML' named entity 'survival' named entity 'doses' named entity 'infants' named entity 'vulnerable' named entity 'Six' named entity 'AML' named entity 'probability' named entity 'confidence interval' named entity 'acute myeloid leukemia' named entity 'Leukemia' named entity 'AML' named entity 'chemotherapeutic drugs' named entity 'infection' named entity 'pulmonary complications' named entity 'supportive care' named entity 'pEFS' named entity 'AML' named entity 'AML' named entity 'G-CSF' named entity 'extramedullary' named entity 'megakaryocytic' named entity 'RUNX1' named entity 'early death' named entity 'risk group' named entity 'morphology' named entity 'mortality rate' named entity 'survival rate' named entity 'hematological' named entity 'RBM15' named entity 'mitoxantrone' named entity 'AML' named entity 'extramedullary' named entity 'megakaryocytic' named entity 'AML' named entity 'leukemia' named entity 'lymphoid tissues' named entity 'high-risk'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software